Treatment resistance in major depression is correlated with increased plasma levels of neurofilament light protein reflecting axonal damage

Susanne Spanier, Hannah M. Kilian, Dora M. Meyer, Thomas E. Schlaepfer

Research output: Contribution to journalArticle

Abstract

Treatment resistant major depression is accompanied with a sizable impact on quality of life with severe consequences for social integrity, individual health and socioeconomic state. In- and outpatient care of patients with treatment resistant major depression remains very challenging for both patients and the health system. One reason is the limited knowledge on the etiology of treatment resistance in major depression resulting difficulties developing efficient treatment strategies for this group of severe depressed patients. Therefore, new focuses on research are needed. Biomarkers reliably reflecting neuropathological processes could help to understand the actual mechanisms in treatment resistance. Neurofilament light protein might be a reliable biomarker of axonal damage in the brain. Due to accumulating evidence that major depression is associated with axonal damage, it is our hypothesis that treatment resistant major depression is correlated with persistent axonal damage within circuits processing affective responses. Axonal damage is reflected by increased levels of neurofilament light protein in plasma. To evaluate our hypothesis, neurofilament light protein will be measured in a group of patients with homogeneous symptomatology of treatment resistant major depression.

Original languageEnglish (US)
Pages (from-to)159-161
Number of pages3
JournalMedical Hypotheses
Volume127
DOIs
StatePublished - Jun 1 2019

Fingerprint

Treatment-Resistant Depressive Disorder
Depression
Biomarkers
Health
Therapeutics
Ambulatory Care
Inpatients
Quality of Life
neurofilament protein L
Brain
Research

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Treatment resistance in major depression is correlated with increased plasma levels of neurofilament light protein reflecting axonal damage. / Spanier, Susanne; Kilian, Hannah M.; Meyer, Dora M.; Schlaepfer, Thomas E.

In: Medical Hypotheses, Vol. 127, 01.06.2019, p. 159-161.

Research output: Contribution to journalArticle

@article{059ed0c27ea542f2b43e6808cfcc28c5,
title = "Treatment resistance in major depression is correlated with increased plasma levels of neurofilament light protein reflecting axonal damage",
abstract = "Treatment resistant major depression is accompanied with a sizable impact on quality of life with severe consequences for social integrity, individual health and socioeconomic state. In- and outpatient care of patients with treatment resistant major depression remains very challenging for both patients and the health system. One reason is the limited knowledge on the etiology of treatment resistance in major depression resulting difficulties developing efficient treatment strategies for this group of severe depressed patients. Therefore, new focuses on research are needed. Biomarkers reliably reflecting neuropathological processes could help to understand the actual mechanisms in treatment resistance. Neurofilament light protein might be a reliable biomarker of axonal damage in the brain. Due to accumulating evidence that major depression is associated with axonal damage, it is our hypothesis that treatment resistant major depression is correlated with persistent axonal damage within circuits processing affective responses. Axonal damage is reflected by increased levels of neurofilament light protein in plasma. To evaluate our hypothesis, neurofilament light protein will be measured in a group of patients with homogeneous symptomatology of treatment resistant major depression.",
author = "Susanne Spanier and Kilian, {Hannah M.} and Meyer, {Dora M.} and Schlaepfer, {Thomas E.}",
year = "2019",
month = "6",
day = "1",
doi = "10.1016/j.mehy.2019.03.022",
language = "English (US)",
volume = "127",
pages = "159--161",
journal = "Medical Hypotheses",
issn = "0306-9877",
publisher = "Churchill Livingstone",

}

TY - JOUR

T1 - Treatment resistance in major depression is correlated with increased plasma levels of neurofilament light protein reflecting axonal damage

AU - Spanier, Susanne

AU - Kilian, Hannah M.

AU - Meyer, Dora M.

AU - Schlaepfer, Thomas E.

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Treatment resistant major depression is accompanied with a sizable impact on quality of life with severe consequences for social integrity, individual health and socioeconomic state. In- and outpatient care of patients with treatment resistant major depression remains very challenging for both patients and the health system. One reason is the limited knowledge on the etiology of treatment resistance in major depression resulting difficulties developing efficient treatment strategies for this group of severe depressed patients. Therefore, new focuses on research are needed. Biomarkers reliably reflecting neuropathological processes could help to understand the actual mechanisms in treatment resistance. Neurofilament light protein might be a reliable biomarker of axonal damage in the brain. Due to accumulating evidence that major depression is associated with axonal damage, it is our hypothesis that treatment resistant major depression is correlated with persistent axonal damage within circuits processing affective responses. Axonal damage is reflected by increased levels of neurofilament light protein in plasma. To evaluate our hypothesis, neurofilament light protein will be measured in a group of patients with homogeneous symptomatology of treatment resistant major depression.

AB - Treatment resistant major depression is accompanied with a sizable impact on quality of life with severe consequences for social integrity, individual health and socioeconomic state. In- and outpatient care of patients with treatment resistant major depression remains very challenging for both patients and the health system. One reason is the limited knowledge on the etiology of treatment resistance in major depression resulting difficulties developing efficient treatment strategies for this group of severe depressed patients. Therefore, new focuses on research are needed. Biomarkers reliably reflecting neuropathological processes could help to understand the actual mechanisms in treatment resistance. Neurofilament light protein might be a reliable biomarker of axonal damage in the brain. Due to accumulating evidence that major depression is associated with axonal damage, it is our hypothesis that treatment resistant major depression is correlated with persistent axonal damage within circuits processing affective responses. Axonal damage is reflected by increased levels of neurofilament light protein in plasma. To evaluate our hypothesis, neurofilament light protein will be measured in a group of patients with homogeneous symptomatology of treatment resistant major depression.

UR - http://www.scopus.com/inward/record.url?scp=85064981277&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064981277&partnerID=8YFLogxK

U2 - 10.1016/j.mehy.2019.03.022

DO - 10.1016/j.mehy.2019.03.022

M3 - Article

C2 - 31088642

AN - SCOPUS:85064981277

VL - 127

SP - 159

EP - 161

JO - Medical Hypotheses

JF - Medical Hypotheses

SN - 0306-9877

ER -